When Dan Adams, Executive Chairman and Global Head of Business Development at Protein Sciences in Meriden, took over 20 years ago, the company was tanking. Today, it’s a different story. The small company of just 40 employees has accomplished what no other biotech company in the world has been able to do. Protein Sciences has created a new flu vaccine called Flublok. What’s unique is that it takes just a few weeks to mass produce (unlike traditional vaccines)— enabling rapid response to pandemic outbreaks that can kill thousands. Now the company has tripled in size and is working on other innovative and potentially game-changing technologies involving more kinds of vaccines and gene therapy.